Cost effectiveness and resource allocation : C/E · 2026
How much do lower respiratory tract infections in adults cost? A hospital-based cost analysis in Colombia.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Castro García Paula Andrea, Moyano Ariza Luisa Fernanda, Vanegas Duarte Esteban Orlando, Quintero Espinosa Juliana, Aguirre Rodríguez Angela Patricia, Londoño Trujillo Darío
Аннотация
BACKGROUND: In Colombia, lower respiratory tract infections (LRTI) are one of the main events of interest to public health. This study aims to describe and quantify the direct medical costs associated with hospital care for LRTI in the Colombian health system.
METHODS: A retrospective observational study using hospital and national databases was conducted to analyze the direct hospital costs of patients with LRTI from the perspective of the Colombian healthcare system. Data was obtained from hospital records and the Individual Registry of Health Services Provision (RIPS). Cost assessment was performed using national databases (Sufficiency for Health Benefits and the Drug Price Information System - SISMED). Costs were classified as follows: consultations, laboratory and imaging costs, procedures, medications, supplies, and hospital stay, segmented by age groups and diagnostic subgroups. The analysis used measures of central tendency and dispersion.
RESULTS: The services of 601 patients from a university hospital and 14,979 hospitalization cases registered in RIPS were analyzed. The findings revealed that costs are concentrated primarily in the population over 60 years of age, especially in treating influenza and pneumonia (J09-J18), accounting for more than 70% of the total cost. According to RIPS, the mean cost per hospitalized patient with LRTI was Int$5,657. At the university hospital, the median cost per patient was Int$7,525 (IQR Int$14,346). Medications and hospital stays were the largest components of the total cost. Additionally, respiratory syncytial virus (RSV) cases had mean hospital costs per patient of Int$7,340, with medications and hospital stays being the main cost drivers.
CONCLUSION: The significant economic burden of LRTI on the Colombian health system, especially among adults over 60 years of age, highlights the need to strengthen public health policies aimed at their prevention and control. It is recommended to emphasize vaccination strategies, optimization of hospital management, and strengthening epidemiological surveillance.
CLINICAL TRIAL NUMBER: Not applicable.
METHODS: A retrospective observational study using hospital and national databases was conducted to analyze the direct hospital costs of patients with LRTI from the perspective of the Colombian healthcare system. Data was obtained from hospital records and the Individual Registry of Health Services Provision (RIPS). Cost assessment was performed using national databases (Sufficiency for Health Benefits and the Drug Price Information System - SISMED). Costs were classified as follows: consultations, laboratory and imaging costs, procedures, medications, supplies, and hospital stay, segmented by age groups and diagnostic subgroups. The analysis used measures of central tendency and dispersion.
RESULTS: The services of 601 patients from a university hospital and 14,979 hospitalization cases registered in RIPS were analyzed. The findings revealed that costs are concentrated primarily in the population over 60 years of age, especially in treating influenza and pneumonia (J09-J18), accounting for more than 70% of the total cost. According to RIPS, the mean cost per hospitalized patient with LRTI was Int$5,657. At the university hospital, the median cost per patient was Int$7,525 (IQR Int$14,346). Medications and hospital stays were the largest components of the total cost. Additionally, respiratory syncytial virus (RSV) cases had mean hospital costs per patient of Int$7,340, with medications and hospital stays being the main cost drivers.
CONCLUSION: The significant economic burden of LRTI on the Colombian health system, especially among adults over 60 years of age, highlights the need to strengthen public health policies aimed at their prevention and control. It is recommended to emphasize vaccination strategies, optimization of hospital management, and strengthening epidemiological surveillance.
CLINICAL TRIAL NUMBER: Not applicable.